• Our amnion based products help patients heal quickly, safely and effectively.

  • From chronic and acute wounds to surgical applications and sports medicine, we treat a wide range of patient conditions.

  • Discover the many ways MiMedx® can help improve patients' outcomes.

  • Learn more about why you should invest in the company taking regenerative medicine into the future.

The Second MiMedx EpiFix® Randomized Comparative study published shows 92.5% healing rate over 12 weeks

 

The latest study reiterates the results of other clinical studies that EpiFix® allograft is a clinically and cost effective therapy:

 

"A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers.”
Charles M Zelen, Thomas E Serena, Robert J Snyder

Read the entire study here

 

MiMedx® delivers innovative bioactive healing products for tissue regeneration

MiMedx® is the global premier processor, marketer, and distributor of human amniotic tissue. MiMedx® has distributed over 200,000 amniotic tissue grafts worldwide and achieved profound clinical outcomes in multiple therapeutic areas including ophthalmology, spine, chronic wounds, dental, orthopedic surgery, sports medicine, and urology.  With this groundbreaking human tissue offering that promotes bioactive healing, MiMedx® believes its unmatched knowledge and superior processing of amniotic tissue strategically positions the Company to become the leader in regenerative medicine.

The Company’s patent protected PURION® Process is the foundation of the MiMedx® AmnioFix® and EpiFix® products that serve to regenerate damaged or diseased tissues by delivering human extracellular matrix components, essential growth factors, and specialized mediating cytokines. AmnioFix® and EpiFix® reduce inflammation, reduce scar tissue formation, and enhance soft tissue healing.  The Company’s proprietary PURION® Process dry preserves human amniotic membrane tissue, resulting in minimally manipulated tissue products that address numerous serious unmet medical needs requiring tissue regeneration or healing inside and outside the body. Through the Company’s unique process for dehydrating human amniotic tissues, improved clinical outcomes, increased patient quality of life, and reduced financial burden to the healthcare system are achieved. 

MiMedx® obtains human amniotic membrane tissue that would otherwise be discarded through its placenta donation program.  The “Give the Gift of Healing” placenta donation program allows mothers, delivering healthy babies by planned Caesarean section, to donate their placentas to MiMedx® which would otherwise be discarded by the hospital as medical waste. The MiMedx® staff and all of our resources are dedicated to handling, processing, and delivering the donated tissues to patients. The PURION® processed tissues are safe, effective, and minimally manipulated allografts that are intended for homologous use. 

The MiMedx® allografts produced from the Company’s proprietary PURION® Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing. The grafts can be utilized right out of the package without a complicated thawing process. These critical qualities of the MiMedx® allografts allow hospitals, clinics, and surgeons to immediately provide the appropriate treatment while effectively manage their inventory of allografts. 

MiMedx® is dedicated to the development and support of thoughtful and effective philanthropic programs to help those in underserved medical areas in need of healing.

 

MiMedx® has Moved!

Driven by rapid sales growth and business expansion, MiMedx® has moved to a larger facility to house both its worldwide corporate headquarters and its operations functions...Read More.

The new MiMedx® facility will accommodate all aspects of the Company’s needs in one location with room to grow. The newly renovated facility has over 80,000 square feet dedicated to the development and production of regenerative biomaterials. The Company’s existing facility in Kennesaw, GA, will be maintained for additional capacity and disaster recovery.